Literature DB >> 28784672

Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.

John W McBride1, Nicola Dias2, David Cameron2, Robin E Offord3, Oliver Hartley3,4, Peter Boyd1, Vicky L Kett1, R Karl Malcolm5.   

Abstract

5P12-RANTES, a chemokine analogue that potently blocks the HIV CCR5 coreceptor, is being developed as both a vaginal and rectal microbicide for prevention of sexual transmission of HIV. Here, we report the first pharmacokinetic data for 5P12-RANTES following single-dose vaginal gel administration in sheep. Aqueous gel formulations containing low (1.24-mg/ml), intermediate (6.18-mg/ml), and high (32.0-mg/ml; suspension-type gel) concentrations of 5P12-RANTES were assessed via rheology, syringeability, and in vitro release testing. Following vaginal gel administration to sheep, 5P12-RANTES concentrations were measured in vaginal fluid, vaginal tissue, and serum over a 96-h period. All gels showed non-Newtonian pseudoplastic behavior, with the high-concentration gels exhibiting a greater viscosity and cohesive structure than the intermediate- and low-concentration gels. In in vitro release testing, >90% 5P12-RANTES was released from the low- and intermediate-concentration gels after 72 h. For the high-concentration gel, ∼50% 5P12-RANTES was detected, attributed to protein denaturation during lyophilization and/or subsequent solvation of the protein within the gel matrix. In sheep, 5P12-RANTES concentrations in vaginal fluid, vaginal tissue, and serum increased in a dose-dependent manner. The highest concentrations were measured in vaginal fluid (105 to 107 ng/ml), followed by vaginal tissue (104 to 106 ng/ml). Both of these concentration ranges are several orders of magnitude above the reported half-maximal inhibitory concentrations. The lowest concentration was measured in serum (<102 ng/ml). The 5P12-RANTES pharmacokinetic data are similar to those reported previously for other candidate microbicides. These data, coupled with 5P12-RANTES's potency at picomolar concentrations, its strong barrier to resistance, and the full protection that it was observed to provide in a rhesus macaque vaginal challenge model, support the continued development of 5P12-RANTES as a microbicide.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CCR5 receptor inhibitor; HIV prevention; HIV/AIDS; antiretroviral agents; drug delivery; human immunodeficiency virus; microbicidal proteins; pharmacokinetics; sheep; vaginal gel; vaginal microbicide antiretroviral

Mesh:

Substances:

Year:  2017        PMID: 28784672      PMCID: PMC5610505          DOI: 10.1128/AAC.00965-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  73 in total

Review 1.  A vaginal fluid simulant.

Authors:  D H Owen; D F Katz
Journal:  Contraception       Date:  1999-02       Impact factor: 3.375

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

3.  Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.

Authors:  Diarmaid J Murphy; Delphine Desjardins; Nathalie Dereuddre-Bosquet; Patricia Brochard; Ludivine Perrot; Alain Pruvost; Roger Le Grand; Ole Lagatie; Leen Vanhooren; Maxim Feyaerts; Jens van Roey; R Karl Malcolm
Journal:  J Antimicrob Chemother       Date:  2014-05-26       Impact factor: 5.790

4.  Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.

Authors:  Salim S Abdool Karim; Angela D M Kashuba; Lise Werner; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

5.  A novel approach to administration of peptides in women: Systemic absorption of a GnRH agonist via transvaginal ring delivery system.

Authors:  A B Kimball; E Javorsky; E S Ron; W Crowley; R Langer
Journal:  J Control Release       Date:  2016-04-26       Impact factor: 9.776

Review 6.  Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing.

Authors:  José das Neves; João Pedro Martins; Bruno Sarmento
Journal:  Adv Drug Deliv Rev       Date:  2015-12-28       Impact factor: 15.470

7.  Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model.

Authors:  Milena Veselinovic; C Preston Neff; Leila R Mulder; Ramesh Akkina
Journal:  Virology       Date:  2012-07-24       Impact factor: 3.616

8.  Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (leuprolide) in rats I: absorption by various routes and absorption enhancement.

Authors:  H Okada; I Yamazaki; Y Ogawa; S Hirai; T Yashiki; H Mima
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

9.  Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses.

Authors:  Rhonda M Curran; Louise Donnelly; Ryan J Morrow; Carol Fraser; Gavin Andrews; Martin Cranage; R Karl Malcolm; Robin J Shattock; A David Woolfson
Journal:  Vaccine       Date:  2009-09-10       Impact factor: 3.641

10.  A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.

Authors:  Fabrice Cerini; Hubert Gaertner; Knut Madden; Ilya Tolstorukov; Scott Brown; Bram Laukens; Nico Callewaert; Jay C Harner; Anna M Oommen; John T Harms; Anthony R Sump; Robert C Sealock; Dustin J Peterson; Scott K Johnson; Stephan B Abramson; Michael Meagher; Robin Offord; Oliver Hartley
Journal:  Protein Expr Purif       Date:  2015-10-24       Impact factor: 1.650

View more
  6 in total

1.  Sustained release silk fibroin discs: Antibody and protein delivery for HIV prevention.

Authors:  Burcin Yavuz; Jessica L Morgan; Carolina Herrera; Kristin Harrington; Bernardo Perez-Ramirez; Patricia J LiWang; David L Kaplan
Journal:  J Control Release       Date:  2019-03-12       Impact factor: 9.776

2.  Endogenous Peptide Inhibitors of HIV Entry.

Authors:  Mirja Harms; Manuel Hayn; Fabian Zech; Frank Kirchhoff; Jan Münch
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12

4.  Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES.

Authors:  John W McBride; Peter Boyd; Nicola Dias; David Cameron; Robin E Offord; Oliver Hartley; Vicky L Kett; R Karl Malcolm
Journal:  J Control Release       Date:  2019-02-04       Impact factor: 9.776

5.  Rational CCL5 mutagenesis integration in a lactobacilli platform generates extremely potent HIV-1 blockers.

Authors:  Massimiliano Secchi; Valentina Grampa; Luca Vangelista
Journal:  Sci Rep       Date:  2018-01-30       Impact factor: 4.379

6.  Anti-α4β7 monoclonal antibody-conjugated nanoparticles block integrin α4β7 on intravaginal T cells in rhesus macaques.

Authors:  Sidi Yang; Geraldine Arrode-Bruses; Ines Frank; Brooke Grasperge; James Blanchard; Agegnehu Gettie; Elena Martinelli; Emmanuel A Ho
Journal:  Sci Adv       Date:  2020-08-21       Impact factor: 14.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.